Compare United States Copper Index Fund (CPER) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
United States Copper Index Fund vs 10X Genomics Inc — how do they compare? United States Copper Index Fund trades at $40 (market cap $708.28M), while 10X Genomics Inc trades at $79 (market cap $10.07B). The key difference: 10X Genomics Inc is far larger — about 14.2× United States Copper Index Fund's market cap, and United States Copper Index Fund is more actively traded (339,046 versus 5,657,286). Which is the better fit depends on your goals — on Pluang, investors hold United States Copper Index Fund for 48 Days and 10X Genomics Inc for 92 Days on average.
| CPER | TXG | |
|---|---|---|
Market Cap | $708.28M | $10.07B |
Volume | 339,046 | 5,657,286 |
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $41.43 | $97.74 |
52-Week Low | $30.27 | $11.48 |
Typical Hold Time | 48 Days | 92 Days |
Enterprise Value | — | $9.59B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CPER trades at $39.81, down 0.55% on the day, with a neutral technical signal overall. The stock shows bullish moving averages but neutral oscillators, with key support at $39. Recent news highlights strong copper demand driven by AI infrastructure, though some articles note price volatility. Financial ratios are unavailable in the provided data.
The outlook for CPER is mixed, balancing positive copper demand trends against near-term price pressure. Investment opportunity lies in exposure to the essential metal for AI and electrification, but risks include commodity price swings and operational challenges in the mining sector. Investors should weigh sector momentum against inherent volatility.
10x Genomics (TXG) trades at $76.10, down 5.65% on the day, as technical indicators signal bearish momentum with the stock below key resistance levels. The company shows improving fundamentals with three consecutive quarterly earnings beats and positive operating cash flow of $136M in 2025, though it remains unprofitable with a -12.18% net margin. Recent developments include the launch of Atera spatial biology platform shipments and a patent victory against Parse Biosciences.
TXG presents a mixed investment case with strong product innovation and improving financial trends offset by high valuation metrics and persistent losses. The stock's risk/reward appears balanced near analyst consensus targets, requiring successful execution on Atera commercialization and path to profitability to justify current multiples.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About United States Copper Index Fund
CPER is a commodity ETF that tracks the price of copper futures via the SummerHaven Copper Index. It provides direct exposure to the 'red metal' using a rules-based strategy to select futures contracts, making it a key tool for hedging or betting on industrial growth and electrification.
Read more on CPER →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
